Zymeworks' licensing-driven revenue spike in 2025Q2 ($48.7M) has reversed sharply, with revenue falling to zero in 2026Q2 and gross margin swinging to -18.2% in 2026Q1, indicating the end of its asset-light revenue model.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.62-7.9% vs -$0.57 | $5M+1.2% vs $5M |
Q2 2026 May 7, 2026 | -$0.59-490.0% vs -$0.10 | $2M-90.1% vs $24M |
Q2 2026 Mar 2, 2026 | -$0.55-57.1% vs -$0.35 | $3M-86.9% vs $19M |
Q4 2025 Nov 6, 2025 | -$0.26+13.3% vs -$0.30 | $28M+41.7% vs $19M |
Zymeworks (NASDAQ: ZYME - Get Free Report) and Vericel (NASDAQ: VCEL - Get Free Report) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation. Earnings and Valuation This table compares Zymeworks and Vericel"s
Zymeworks (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zymeworks NASDAQ: ZYME outlined a partnering-focused research strategy, presented updated clinical data for its ZW191 antibody-drug conjugate in platinum-resistant ovarian cancer, and discussed its recently announced collaboration with Roche for the DLL3-targeting T-cell engager ZW209.
Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates Transcript
Benchmark ZYME against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Zymeworks Inc. (ZYME)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $29.63 | $2.18B | -14.42 | 38.87% | -404% | -72.07% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $18.28 | $2.3B | -5.23 | -4.26% | -445% | -90.04% | — | |
| $29.41 | $1.75B | -4.71 | 48.03% | -264.76% | -34.63% | — | |
| $0.38 | $5.79M | -0.14 | — | — | -1270.11% | — | |
| $291.31 | $514.68B | 49.87 | 8.57% | 15.68% | — | 2.26% |
Zymeworks Inc. (ZYME) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Zymeworks Inc. (ZYME) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 29, 2026·SEC
May 14, 2026·SEC
Get notified when ZYME posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Zymeworks Inc. (ZYME) stock FAQ — growth, dividends, profitability & financials explained
Zymeworks Inc. (ZYME) reported $37.1M in revenue over the trailing twelve months. Revenue was $106.0M in fiscal year 2025. That is 6245% more than the $1.7M of fiscal year 2014.
Zymeworks Inc. (ZYME) revenue fell by 69.8% over the trailing twelve months, compared with the twelve months before.
No. Zymeworks Inc. (ZYME) reported a net loss of $150.0M over the trailing twelve months.
Zymeworks Inc. (ZYME) had a return on equity (ROE) of -72.1% over the trailing twelve months. A negative ROE means the company lost money over the period.
Zymeworks Inc. (ZYME) had negative free cash flow of $120.0M over the trailing twelve months.
